Assessment of Thrombin Inhibitor Efficacy in a Novel Rabbit Model of Simultaneous Arterial and Venous Thrombosis

Summary

The importance of thrombin in arterial and venous thrombosis renders thrombin inhibition an important therapeutic target. Identification of novel inhibitors requires an appropriate animal model. We modified a previously reported rat arterial thrombosis model to allow simultaneous assessment of the arterial and venous antithrombotic efficacies of heparin, hirudin, hirulog, a novel thrombin inhibitor H-(N-Me-D-Phe)-Pro-L-trans-4-aminocyclohexyl-Gly-[CO-CO]-NHCH₃ (L-370,518) and the factor X_a inhibitor tick anticoagulant peptide in rabbits. Thrombosis was induced through application of 70% ferric chloride to the femoral artery and jugular vein. Incidence of occlusion, thrombus weight, aPTT and plasma inhibitor concentrations were determined. Heparin was efficacious in preventing arterial and venous occlusive thrombosis but at a dose that profoundly elevated aPTT. On a molar dosing basis, the approximate order of potency of the thrombin and factor X_a inhibitors was similar in artery and vein: hirudin>tick anticoagulant peptide>hirulog≥L-370,518. Data suggested that compounds tended to be more potent in preventing venous thrombosis than arterial. This thrombin-dependent model is an economical and efficient approach to arterial and venous antithrombotic efficacy screening that eliminates variabilities encountered when multiple model/multiple animal strategies are employed.

• References

• 1 Fenton II JW, Ofosu FA, Moon DG, Maraganore JM. Thrombin structure and function: why thrombin is the primary target for antithrombotics.. Blood Coagul Fibrinolysis 1991; 2: 69-75.
• 2 Klement P, Borm A, Hirsh J, Maraganore J, Wilson G, Weitz J. The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model.. Thromb Haemost 1992; 68: 64-8.
• 3 Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, de Bono D, Ferguson J, Willerson JT, Strony J, Ganz P, Cohen MD, Raymond R, Fox I, Maraganore J, Adelman B. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty.. Circulation 1993; 87: 1622-9.
• 4 Hirsh J, Salzman EW, Marder VJ. Treatment of venous thromboembolism. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice.. Colman RW, Hirsh J, Marder, VJ, Salzman EW. eds. JB Lippincott Company; Philadelphia, PA: 1994. pp 1346-66.
• 5 Teitel JM, Rosenberg RD. Protection of factor X_a from neutralization by the heparin-antithrombin complex.. J Clin Invest 1983; 71: 1383-91.
• 6 Fenton II JW, Ofosu FA, Brezniak DV, Hassouna HI. Understanding thrombin and hemostasis.. Hematol Oncol Clin North Am 1993; 7: 1107-19.
• 7 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.. J Clin Invest 1990; 86: 385-91.
• 8 Markwardt F. Development of hirudin as an antithrombotic agent.. Semin Thromb Hemost 1989; 15: 269-82.
• 9 Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton II JW. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin.. Biochemistry 1990; 29: 7095-101.
• 10 Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor X_a.. Science 1990; 248: 593-6.
• 11 Vlasuk GP. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor X_a.. Thromb Haemost 1993; 70: 212-6.
• 12 Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride.. Thromb Res 1990; 60: 269-80.
• 13 Broersma RJ, Kutcher LW, Heminger EF. The effect of thrombin inhibition in a rat arterial thrombosis model.. Thromb Res 1991; 64: 405-12.
• 14 Lauwereys M, Stanssens P, Lambeir AM, Messens J, Dempsey E, Vlasuk GP. Ecotin as a potent factor X_a inhibitor.. Thromb Haemost 1993; 69: 783.
• 15 Brady SF, Lewis SD, Colton CD, Stauffer KJ, Sisko JT, Ng AS, Homnick CF, Bogusky MJ, Shafer JA, Veber DF, Nutt RF. In: Peptides: Chemistry, Structure and Biology. Proceedings of the 14th American Peptide Symposium.. Kaumaya PTP, Hodges RS. eds. Mayflower Scientific Limited; 1996. pp 331-3.
• 16 Lewis SD, Ng AS, Lyle EA, Mellott MJ, Appleby SD, Brady SF, Stauffer KJ, Sisko JT, Mao SS, Veber DF, Nutt RF, Lynch JJ, Cook JJ, Gardell SJ, Shafer JA. Inhibition of thrombin by peptides containing lysyl-α-keto carbonyl derivatives.. Thromb Haemost 1995; 74: 1107-12.
• 17 Neeper MP, Waxman L, Smith DE, Schulman CA, Sardana M, Ellis RW, Schaffer LW, Siegl PKS, Vlasuk GP. Characterization of recombinant tick anticoagulant peptide. A highly selective inhibitor of blood coagulation factor X_a.. J Biol Chem 1990; 265: 17746-52.
• 18 Lehman ED, Joyce JG, Bailey FJ, Markus HZ, Schultz LD, Dunwiddie CT, Jacobson MA, Miller WJ. Expression, purification and characterization of multigram amounts of a recombinant hybrid HV1-HV2 hirudin variant expressed in Saccharomyces cerevisiae.. Protein Expr Purif 1993; 4: 247-55.
• 19 Breddin HK. Thrombosis and Virchow’s Triad: what is established?. Semin Thromb Hemost 1989; 15: 237-9.
• 20 Kurz KD, Smith T, Moore RA, Main BW. Comparison of thrombin inhibitors in rat models of thrombosis and thrombolysis.. FASEB J 1991; 6: A520.
• 21 Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition.. Circulation 1990; 81: 219-25.
• 22 Schaffer LW, Davidson JT, Vlasuk GP, Siegl PKS. Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor X_a in a primate model of arterial thrombosis.. Circulation 1991; 84: 1741-8.
• 23 Boneu B, Buchanan MR, Cade JF, Van Ryn J, Fernandez FF, Ofosu FA, Hirsh J. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo.. Thromb Res 1985; 40: 81-9.
• 24 Kelly AB, Maraganore JM, Bourdon P, Hanson SR, Harker LA. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin.. Proc Natl Acad Sci USA 1992; 89: 6040-4.
• 25 Walenga JM, Pifarre R, Hoppensteadt DA, Fareed J. Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerations.. Semin Thromb Hemost 1989; 15: 316-33.
• 26 Dunwiddie CT, Smith DE, Nutt EM, Vlasuk GP. Anticoagulant effects of the selective factor X_a inhibitors tick anticoagulant peptide and antistasin in the aPTT assay are determined by the relative rate of prothrombinase inhibition.. Thromb Res 1991; 64: 787-94.
• 27 Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infaction (TIMI) 5 trial.. J Am Coll Cardiol 1994; 23: 993-1003.
• 28 Antman EM. TIMI 9A Investigators.. Hirudin in acute myocardial infarction. Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial.. Circulation 1994; 90: 1624-30.
• 29 Jackson MR, Reid TJ, Tang DB, O’Donnell SD, Gomez ER, Alving BM. Antithrombotic effects of hirulog in a rat carotid endarterectomy model.. J Surg Res 1996; 60: 15-22.
• 30 Lyle EM, Fujita T, Conner MW, Connolly TM, Vlasuk GP, Lynch Jr JJ. Effect of inhibitors of factor X_a or platelet adhesion, heparin, and aspirin on platelet deposition in an atherosclerotic rabbit model of angioplasty injury.. J Pharmacol Toxicol Meth 1995; 33: 53-61.
• 31 Vlasuk GP, Ramjit D, Fujita T, Dunwiddie CT, Nutt EM, Smith DE, Shebuski RJ. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor X_a inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis.. Thromb Haemost 1991; 65: 257-62.
• 32 Fioravanti C, Burkholder D, Francis B, Siegl PKS, Gibson RE. Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis.. Thromb Res 1993; 71: 317-24.
• 33 Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ, Cohen M, Chapekis A, Gold HK, Tannenbaum MA, Rao AK, Debowey D, Schwartz D, Henis M, Chesebro J. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.. Circulation 1994; 89: 1557-66.
• 34 The GUSTO IIb Investigators.. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes.. N Engl J Med 1996; 335: 775-63.
• 35 Sharma GVRK, Lapsley D, Vita JA, Sharma S, Coccio E, Adelman B, Loscalzo J. Usefulness and tolerability of hirulog, a direct thrombin inhibitor, in unstable angina pectoris.. Am J Cardiol 1993; 72: 1357-60.
• 36 Lidón RM, Théroux P, Juneau M, Adelman B, Maraganore J. Initial expe rience with a direct antithrombin, hirulog, in unstable angina. Anticoagulant, antithrombotic and clinical effects.. Circulation 1993; 88: 1495-501.
• 37 Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Soria J, Soria C, Camez A, Mirshahl MC, Bassand JP. A pilot study of subcutaneous recombinant hirudin (HBW023) in the treatment of deep vein thrombosis.. Thromb Haemost 1994; 71: 558-62.
• 38 Parent F, Bridey F, Dreyfus M, Musset D, Grimon G, Meyer D, Simonneau G. Treatment of severe venous thromboembolism with intravenous hirudin (HBW023): an open pilot study.. Thromb Res 1992; 65 (Suppl. 01) S118.
• 39 Eriksson BI, Kälebo P, Ekman S, Lindbratt S, Kerry R, Close P. Direct thrombin inhibition with rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement.. Thromb Haemost 1994; 72: 227-31.
• 40 Ginsberg JS, Hirsh J, Gent M, McKinnon B, Turpie AGG, Levine M, Powers P, Weitz J, Findlen K, Neemeh J, Buller H, Adelman B, Maraganore J, Fox I. A phase II study of hirulog in the prevention of venous thrombosis after major hip or knee surgery.. Circulation 1992; 86: I409.